Background: Interleukin-21 (IL-21) is an immunostimulatory cytokine showing promising results in phase II clinical trials for cancer immunotherapy. IL-21 also enhances anti-viral immunity in HIV/SIV infections. It is a suitable candidate that can be targeted by the kick and kill strategy to boost immunity to eliminate HIV. This study focused on developing an agonistic monoclonal antibody (mAb) to human IL-21 (hIL-21) that enhances the anti-viral function of hIL-21.
Methods: A hIL-21-dependent Ba/F3 cell line proliferation assay was used to screen a library of anti-hIL-21 mAbs to identify agonistic clones. Binding of the agonist mAb to hIL-21 was characterized by Surface Plasmon Resonance (SPR) and crystallography. To test the anti-HIV function of the mAb, peripheral blood mononuclear cells (PBMCs; n=5) from HIV infected patients on antiretroviral therapy (ART>3 years, CD4+ T-cell count>500/µL, viral load<50 copies/mL) were stimulated with MHC-I-restricted gag peptides in the presence of hIL-21 and the mAb. Cytotoxicity of natural killer (NK) and CD8+ T cells were analyzed by measuring intracellular granzyme B and perforin expression by flow cytometry (FACS). The phamacokinetics and phamacodynamics of the mAb were studied in mice humanized with hIL-21 and the hIL-21 receptor (hIL-21R) and infected with lymphocytic choriomeningitis virus (LCMV). Bioavailability (BA) of hIL-21 with the mAb was measured by enzyme-linked immunosorbent assay. Agonistic effect of mAb was determined by quantifying virus-specific CD8+ T-cell response by FACS and viral load by plaque assay.
Results: We identified a mAb SG1 that enhanced hIL-21’s activity ≥10 folds in the Ba/F3 cell proliferation assay. It bound to hIL-21 with an affinity of 7.1E-11(KD). Crystal structure and protein docking stimulation revealed that SG1 changed the conformation of hIL-21 to suit its binding to the receptor. In cultured PBMCs from HIV-infected patients, SG1 significantly increased the cytotoxicity of NK and CD8+ T cells by 5-10 folds. In the chronic LCMV infection, SG1 increased the BA of hIL-21 >50 folds. An enhanced generation of functional virus-specific CD8+ T cells led to early resolution of the infection.
Conclusions: The high-affinity mAb SG1 has a unique function to enhance hIL-21’s activity by changing its conformation and increasing the BA in vivo. Superagonist mAb SG1 promotes the anti-viral function of hIL-21 in vitro and in vivo. SG1 might be used in a kick and kill approach to eliminate HIV latency.